BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Mechanism of Action
Chemokine Receptor Type 4 Interactions
Pharmacologic Class:
Chemokine Receptor Type 4 Interaction
Clinical Trials (5)
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Started Oct 2024
22 enrolled
T Cell LymphomaT-cell Lymphoma
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Started May 2023
10 enrolled
Cutaneous T Cell LymphomaMycosis Fungoides
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Started Aug 2021
34 enrolled
Cutaneous T-Cell Lymphoma, RelapsedCutaneous T-Cell Lymphoma Refractory
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Started Sep 2019
150 enrolled
Leukemia/LymphomaCutaneous T Cell LymphomaATLL
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Started Aug 2016
36 enrolled
Solid TumorCancerCarcinoma